CPBTD
VKTX icon

Central Pacific Bank - Trust Division’s Viking Therapeutics VKTX Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,003
Closed -$239K – 983
2024
Q1 		$239K Buy
+3,003
New +$134K 0.03% 510

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Central Pacific Bank - Trust Division's VKTX Position: Q2 2024 in Review

Central Pacific Bank - Trust Division sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 3,003 shares — an estimated $239K sold.

Central Pacific Bank - Trust Division first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $239K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Central Pacific Bank - Trust Division reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Central Pacific Bank - Trust Division sold 3,003 Viking Therapeutics shares in Q2 2024, an estimated $239K.
  • Central Pacific Bank - Trust Division first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
  • Central Pacific Bank - Trust Division's Viking Therapeutics position peaked at $239K in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Central Pacific Bank - Trust Division's 13F filing for Q2 2024, filed 30 Jul 2024.